FI59596C - Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin - Google Patents
Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin Download PDFInfo
- Publication number
- FI59596C FI59596C FI750122A FI750122A FI59596C FI 59596 C FI59596 C FI 59596C FI 750122 A FI750122 A FI 750122A FI 750122 A FI750122 A FI 750122A FI 59596 C FI59596 C FI 59596C
- Authority
- FI
- Finland
- Prior art keywords
- butyl
- oxobutyl
- xanthine
- therapeutic
- effect
- Prior art date
Links
- -1 3-OXOBUTYL Chemical class 0.000 title description 12
- 238000004458 analytical method Methods 0.000 title description 2
- 230000001225 therapeutic effect Effects 0.000 title 2
- KTXQLVQIEDPKAS-UHFFFAOYSA-N 1,3-dibutyl-7-(3-oxobutyl)purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1N(CCC(C)=O)C=N2 KTXQLVQIEDPKAS-UHFFFAOYSA-N 0.000 claims description 8
- FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- HDAPVDGMACVEKL-UHFFFAOYSA-N 1,3-dibutyl-7h-purine-2,6-dione Chemical compound O=C1N(CCCC)C(=O)N(CCCC)C2=C1NC=N2 HDAPVDGMACVEKL-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 description 17
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229940075420 xanthine Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 229960001476 pentoxifylline Drugs 0.000 description 5
- 206010002091 Anaesthesia Diseases 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 229920000609 methyl cellulose Polymers 0.000 description 4
- 239000001923 methylcellulose Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- MMPOTNFPDMJTRR-UHFFFAOYSA-N OOOOOOOOOOO Chemical compound OOOOOOOOOOO MMPOTNFPDMJTRR-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229950009941 chloralose Drugs 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- AVGSFNMHPGQZEQ-UHFFFAOYSA-N 1,3-dibutyl-8-(3-oxobutyl)-7H-purine-2,6-dione Chemical compound O=C(CCC1=NC=2N(C(N(C(C2N1)=O)CCCC)=O)CCCC)C AVGSFNMHPGQZEQ-UHFFFAOYSA-N 0.000 description 2
- TVZXSTTUKANBFF-UHFFFAOYSA-N 8-butyl-3,7-dihydropurine-2,6-dione Chemical compound N1C(=O)NC(=O)C2=C1N=C(CCCC)N2 TVZXSTTUKANBFF-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000012754 cardiac puncture Methods 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 125000005188 oxoalkyl group Chemical group 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- WDNTXUDSVHZABP-UHFFFAOYSA-N 1,3-dimethyl-7-(3-oxobutyl)purine-2,6-dione Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2CCC(=O)C WDNTXUDSVHZABP-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- BYMZEXPKRSJSSO-UHFFFAOYSA-N 4-azido-n-[2-[2-(4-azido-2-nitroanilino)ethylsulfonylsulfanyl]ethyl]-2-nitroaniline Chemical compound [O-][N+](=O)C1=CC(N=[N+]=[N-])=CC=C1NCCSS(=O)(=O)CCNC1=CC=C(N=[N+]=[N-])C=C1[N+]([O-])=O BYMZEXPKRSJSSO-UHFFFAOYSA-N 0.000 description 1
- UCQLUIDKDICHSB-UHFFFAOYSA-N 8,8-dibutyl-3H-purine-2,6-dione Chemical compound C(CCC)C1(N=C2NC(NC(C2=N1)=O)=O)CCCC UCQLUIDKDICHSB-UHFFFAOYSA-N 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 206010005746 Blood pressure fluctuation Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- DTAFLBZLAZYRDX-UHFFFAOYSA-N OOOOOO Chemical compound OOOOOO DTAFLBZLAZYRDX-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- OJYGBLRPYBAHRT-IPQSZEQASA-N chloralose Chemical compound O1[C@H](C(Cl)(Cl)Cl)O[C@@H]2[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]21 OJYGBLRPYBAHRT-IPQSZEQASA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001834 epinephrinelike Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229960004583 pranlukast Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2402908 | 1974-01-22 | ||
| DE2402908A DE2402908C2 (de) | 1974-01-22 | 1974-01-22 | 7-(3-Oxobutyl)-1,3-di-(n-butyl)-xanthin und Verfahren zu seiner Herstellung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI750122A7 FI750122A7 (en:Method) | 1975-07-23 |
| FI59596B FI59596B (fi) | 1981-05-29 |
| FI59596C true FI59596C (fi) | 1981-09-10 |
Family
ID=5905372
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI750122A FI59596C (fi) | 1974-01-22 | 1975-01-20 | Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin |
| FI801875A FI801875A7 (fi) | 1974-01-22 | 1975-01-20 | 7-(oksoalkyyli)-1,3-dialkyyliksantiinit, niiden valmistusmenetelmä ja näitä yhdisteitä sisältävät lääkeianeet. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI801875A FI801875A7 (fi) | 1974-01-22 | 1975-01-20 | 7-(oksoalkyyli)-1,3-dialkyyliksantiinit, niiden valmistusmenetelmä ja näitä yhdisteitä sisältävät lääkeianeet. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US4242345A (en:Method) |
| JP (1) | JPS5912677B2 (en:Method) |
| AR (1) | AR207462A1 (en:Method) |
| AT (1) | AT338286B (en:Method) |
| BE (1) | BE824665A (en:Method) |
| CA (1) | CA1068693A (en:Method) |
| CH (1) | CH608236A5 (en:Method) |
| FI (2) | FI59596C (en:Method) |
| FR (1) | FR2258183B1 (en:Method) |
| GB (1) | GB1441562A (en:Method) |
| HU (1) | HU169012B (en:Method) |
| NL (1) | NL184330C (en:Method) |
| YU (1) | YU15175A (en:Method) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2507554A1 (de) * | 1975-02-21 | 1976-09-02 | Wuelfing J A Fa | 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE2507555A1 (de) * | 1975-02-21 | 1976-09-02 | Wuelfing J A Fa | 7-(oxoalkyl)-1,3-dialkylxanthine, verfahren zu ihrer herstellung und diese verbindung enthaltende arzneimittel |
| DE2967632D1 (en) * | 1978-04-22 | 1986-12-04 | Beecham Wuelfing Gmbh & Co Kg | Use of a xanthine derivate in the manufacture of a medicament |
| IL59665A0 (en) * | 1979-04-05 | 1980-06-30 | Wuelfing J Kg | Xanthine derivatives,process for their preparation and their use in pharmaceutical compositions |
| EP0157098A1 (en) * | 1980-06-21 | 1985-10-09 | Beecham Wuelfing GmbH & Co KG | Xanthine derivatives, pharmaceuticals compositions containing them and a process for their preparation |
| GB8418430D0 (en) * | 1984-07-19 | 1984-08-22 | Beecham Wuelfing Gmbh & Co Kg | Treatment |
| JPS63225317A (ja) * | 1986-10-06 | 1988-09-20 | Hoechst Japan Kk | 抗消化性潰瘍剤 |
| US4965271A (en) * | 1986-12-31 | 1990-10-23 | Hoechst Roussel Pharmaceuticals, Inc. | Method of inhibiting the activity of leukocyte derived cytokines |
| US5096906A (en) * | 1986-12-31 | 1992-03-17 | University Of Virginia Alumni Patents Foundation | Method of inhibiting the activity of leukocyte derived cytokines |
| JP2661666B2 (ja) * | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
| GB8826595D0 (en) * | 1988-11-14 | 1988-12-21 | Beecham Wuelfing Gmbh & Co Kg | Active compounds |
| US5321029A (en) * | 1988-11-14 | 1994-06-14 | Beecham-Wuelfing Gmbh & Co.K.G. | Xanthines |
| CA2030112A1 (en) * | 1989-11-24 | 1991-05-25 | Yasuo Ito | Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same |
| EP0484785B1 (en) * | 1990-11-07 | 1996-05-22 | Hoechst-Roussel Pharmaceuticals Incorporated | Use of xanthines for the preparation of a medicament effective for inhibiting the replication of human retroviruses |
| US6420374B1 (en) | 1990-11-30 | 2002-07-16 | Fred Hutchinson Cancer Research Center | Use of xanthines as immunosuppressants and to inhibit allograft reactions |
| MX9203323A (es) * | 1991-07-11 | 1994-07-29 | Hoechst Ag | El empleo de derivados de xantina para el tratamiento de lesiones secundarias de las celulas nerviosas y trastornos funcionales despues de traumas craneo-cerebrales. |
| ES2096115T3 (es) * | 1992-02-22 | 1997-03-01 | Hoechst Ag | Uso de derivados de xantina para el tratamiento de lesiones musculares despues de la interrupcion completa de la circulacion sanguinea. |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
| US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
| US6448235B1 (en) | 1994-07-11 | 2002-09-10 | University Of Virginia Patent Foundation | Method for treating restenosis with A2A adenosine receptor agonists |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| US6322771B1 (en) | 1999-06-18 | 2001-11-27 | University Of Virginia Patent Foundation | Induction of pharmacological stress with adenosine receptor agonists |
| US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
| CA2460911C (en) | 2001-10-01 | 2011-08-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
| CA2576826C (en) * | 2004-08-02 | 2014-09-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| US7576069B2 (en) * | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| US8178509B2 (en) * | 2006-02-10 | 2012-05-15 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2761863A (en) * | 1956-09-04 | Lower-alkyl | ||
| CA557342A (en) | 1958-05-13 | Doebel Karl | Process for the manufacture of novel xanthine derivatives | |
| US2756229A (en) * | 1956-07-24 | Xanthine derivatives | ||
| FR4791E (fr) | 1900-06-29 | 1905-10-16 | Eugene Fournier | Lampe à pétrole perfectionnée pour chauffage intensif dite: "la naphteuse" |
| DE926788C (de) | 1952-11-07 | 1955-04-25 | Geigy Ag J R | Verfahren zur Herstellung von 1, 3-dialkylierten 7-Oxyalkyl-xanthinabkoemmlingen |
| GB759174A (en) * | 1952-11-07 | 1956-10-17 | Geigy Ag J R | Improvements in diuretic acting xanthine derivatives |
| GB759981A (en) * | 1953-09-09 | 1956-10-24 | Roche Products Ltd | Process for the manufacture of xanthine derivatives |
| CH325292A (de) | 1953-10-21 | 1957-10-31 | Geigy Ag J R | Verfahren zur Herstellung von 7-Oxyalkyl-xanthinderivaten |
| US3737433A (en) * | 1964-09-05 | 1973-06-05 | Albert Ag Chem Werke | Certain oxoalkyldimethylxanthines |
| DE2234202A1 (de) | 1972-07-12 | 1974-01-24 | Albert Ag Chem Werke | Verfahren zur herstellung von oxoalkylxanthinen |
| DE2330742C2 (de) | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| DE2457666A1 (de) * | 1974-12-06 | 1976-06-10 | Hoechst Ag | Arzneimittel, verfahren zur herstellung von dafuer geeigneten wirkstoffen und diese oxoalkyl-dialkyl-xanthine |
| JPS5233120A (en) * | 1975-09-10 | 1977-03-14 | Nisshin Steel Co Ltd | Double coiled automobile steel pipe covered with heat flexible plastic resin |
-
1974
- 1974-11-04 CH CH1474974A patent/CH608236A5/xx not_active IP Right Cessation
- 1974-11-14 NL NLAANVRAGE7414887,A patent/NL184330C/xx not_active IP Right Cessation
- 1974-11-20 AT AT929674A patent/AT338286B/de not_active IP Right Cessation
- 1974-12-19 CA CA216,460A patent/CA1068693A/en not_active Expired
-
1975
- 1975-01-01 AR AR257365A patent/AR207462A1/es active
- 1975-01-16 GB GB190075A patent/GB1441562A/en not_active Expired
- 1975-01-20 FI FI750122A patent/FI59596C/fi not_active IP Right Cessation
- 1975-01-20 FI FI801875A patent/FI801875A7/fi not_active Application Discontinuation
- 1975-01-21 HU HUWU17A patent/HU169012B/hu unknown
- 1975-01-22 JP JP50010126A patent/JPS5912677B2/ja not_active Expired
- 1975-01-22 FR FR7501906A patent/FR2258183B1/fr not_active Expired
- 1975-01-22 YU YU00151/75A patent/YU15175A/xx unknown
- 1975-01-22 BE BE152617A patent/BE824665A/xx not_active IP Right Cessation
-
1978
- 1978-09-19 US US05/943,815 patent/US4242345A/en not_active Expired - Lifetime
-
1979
- 1979-06-04 US US06/045,381 patent/US4291037A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| BE824665A (fr) | 1975-05-15 |
| US4242345A (en) | 1980-12-30 |
| AT338286B (de) | 1977-08-10 |
| CH608236A5 (en:Method) | 1978-12-29 |
| ATA929674A (de) | 1976-12-15 |
| YU15175A (en) | 1982-06-30 |
| GB1441562A (en) | 1976-07-07 |
| CA1068693A (en) | 1979-12-25 |
| NL184330C (nl) | 1989-06-16 |
| NL184330B (nl) | 1989-01-16 |
| FI750122A7 (en:Method) | 1975-07-23 |
| JPS5912677B2 (ja) | 1984-03-24 |
| NL7414887A (nl) | 1975-07-24 |
| FR2258183A1 (en:Method) | 1975-08-18 |
| US4291037A (en) | 1981-09-22 |
| FR2258183B1 (en:Method) | 1978-07-28 |
| FI59596B (fi) | 1981-05-29 |
| AR207462A1 (es) | 1976-10-08 |
| JPS50101386A (en:Method) | 1975-08-11 |
| FI801875A7 (fi) | 1981-01-01 |
| HU169012B (en:Method) | 1976-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI59596C (fi) | Foerfarande foer framstaellning av en terapeutiskt anvaendbar 7-(3-oxobutyl)-1,3-di-(n-butyl)xantin | |
| Hagelberg et al. | Toxicokinetics of ochratoxin A in several species and its plasma‐binding properties | |
| PL136579B1 (en) | Process for preparing derivatives of 2-propoxymethylguanine | |
| CN101675927A (zh) | 治疗分子及方法-1 | |
| DK160269B (da) | Analogifremgangsmaade til fremstilling af 4-aroyl-1,3-dihydro-2h-imidazol-2-oner eller et farmaceutisk acceptabelt metalsalt eller basisk ammoniumsalt deraf | |
| WO2012099557A2 (en) | Fatty acid inhibitors | |
| JP2023517541A (ja) | 不整脈の治療のためのニコチンアミドモノヌクレオチド誘導体 | |
| CA2454654A1 (en) | Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use | |
| KR900000370B1 (ko) | 티아졸론 및 이의 제조방법 | |
| HUT63610A (en) | Process for producing immune modifying n-phenyl-2-cyano-3-hydroxycrotonic acid derivatives and pharmaceutical compositions comprising such compounds | |
| KR900000369B1 (ko) | 헤테로사이클릭 옥사졸론 및 이의 제조방법 | |
| JP2865255B2 (ja) | １，２，３，４，１０，１４ｂ‐ヘキサヒドロジベンゾ〔ｃ，ｆ〕ピラジノ〔１，２‐ａ〕アゼピノ誘導体及び１０‐アザ，１０‐オキサ及び１０‐チア類似体 | |
| RU2108100C1 (ru) | Иммуномодулятор | |
| PT89904B (pt) | Processo para a preparacao de derivados de 4-substituida pirazolo {3,4-d}pirimidina e de composicoes farmaceuticas que os contem | |
| Fisher et al. | Influence of alkylating agents on kidney erythropoietin production | |
| FI59250C (fi) | Foerfarande foer framstaellning av cancerostatiskt och immunstimulerande verkande 4-imino-1,3-diazabicyklo-(3,1,0)-hexan-2-on | |
| FI62089B (fi) | Foerfarande foer framstaellning av pao det perifera blodomloppet verkande 7-(n-(3-fenoxi-2-hydroxipropyl)-n-amino)-1,3-dialkyl-xantinderivat | |
| RU2084449C1 (ru) | 1-бензил-2-оксотриптамин гидрохлорид и его производные, обладающие гепатозащитной активностью | |
| Morikawa et al. | 5-Isoquinolinesulfonamide derivatives. 2. Synthesis and vasodilatory activity of N-(2-aminoethyl)-5-isoquinoline sulfonamide derivatives | |
| PL118238B1 (en) | Process for preparing novel amides of cinnamic acid | |
| CN106038562A (zh) | 一种治疗类风湿性关节炎的药物 | |
| Mirskova et al. | 2-Hydroxyethylammonium Salts of Organylsulphanyl (sylphonyl) acetic Acids as Novel Pharmacologically Active Compounds | |
| DE2921844A1 (de) | Neue nitrosoharnstoff-verbindungen, ein verfahren zu deren herstellung sowie therapeutische zubereitung | |
| AU2004298907A1 (en) | Use of a compound having two gold (I) atoms each covalently bonded to a carbon atom in a covalent link connecting the two gold (I) atoms for the treatment of cancer | |
| RU2539301C1 (ru) | (4-бромфенил)этилиденгидразид 2-[6-метил-1-(тиетан-3-ил)урацил-3-ил]уксусной кислоты, проявляющий гипотензивную активность |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM | Patent lapsed |
Owner name: WUELFING, JOHANN A. |